Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29767119 | 0.86 | MEN1 (0.56) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| SCHEMBL7368527 | 0.83 | MEN1 (0.71) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| SCHEMBL31369939 | 0.83 | MEN1 (0.71) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| SCHEMBL1807496 | 0.82 | MEN1 (0.61) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| Acetic Acid SCHEMBL8720053 | 0.81 | MEN1 (0.68) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| SCHEMBL5308861 | 0.79 | MEN1 (0.66) | MEN1KMT2AKDM4EALDH1A1TDP1 | |
| SCHEMBL2341547 | 0.78 | TACR1 (0.59) | MEN1KMT2AKDM4EALDH1A1HTT | |
| SCHEMBL27570857 | 0.78 | MEN1 (0.63) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| SCHEMBL8436952 | 0.77 | CHRM2 (0.53) | MEN1KMT2AKDM4EHDAC3HDAC1 | |
| SCHEMBL27554492 | 0.76 | MEN1 (0.54) | MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020247679-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20130109581-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | NOVARTIS AG (CH) | 2013-05-02 | — | — | US | disclosed |
| EP-1931695-B1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2013-04-10 | — | — | EP | disclosed |
| EP-1653844-B1 | PRION-SPECIFIC PEPTIDE REAGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2496947-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | Novartis AG (CH) | 2012-09-12 | — | — | EP | disclosed |
| US-20120027677-A1 | Prion-specific peptoid reagents | NOVARTIS AG | 2012-02-02 | — | — | US | disclosed |
| EP-2383281-A2 | Prion-specific peptoid reagents | Novartis AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| US-20110189692-A1 | ASSAY FOR PATHOGENIC CONFORMERS | NOVARTIS AG | 2011-08-04 | — | — | US | disclosed |
| WO-2011057029-A1 | POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| EP-2282753-A1 | ASSAY FOR PATHOGENIC CONFORMERS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| EP-1848830-A2 | OSPLATION OF PATHOGENIC PRIONS | Novartis Vaccines and Diagnostics, Inc. (US) | 2007-10-31 | — | — | EP | disclosed |
| US-20070087972-A1 | Prion-specific peptoid reagents | NOVARTIS AG (CH) | 2007-04-19 | — | — | US | disclosed |
| WO-2006086799-A2 | PRION-SPECIFIC PEPTIDE REAGENTS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006076497-A2 | OSPLATION OF PATHOGENIC PRIONS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076683-A2 | ISOLATION AND DETECTION OF PATHOGENIC PRIONS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006076687-A2 | ELISA ASSAYS USING PRION-SPECIFIC PEPTIDE REAGENTS | NOVARTIS VACCINES AND DIAGNOSTICS INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1653844-A2 | PRION-SPECIFIC PEPTIDE REAGENTS | CHIRON CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| US-20060035242-A1 | Prion-specific peptide reagents | CHIRON CORPORATION | 2006-02-16 | — | — | US | disclosed |
| US-20050118645-A1 | Prion-specific peptide reagents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-06-02 | — | — | US | disclosed |
| WO-2005016127-A2 | PRION-SPECIFIC PEPTIDE REAGENTS | CHIRON CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070087972-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | MEN1 2738/4885KMT2A 4687/4885KDM4E 4426/4885 |
| US-20120027677-A1 | Prion-specific peptoid reagents | PRNP, PARL, PCNP | MEN1 2738/4885KMT2A 4687/4885KDM4E 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.